Klin Farmakol Farm. 2015;29(3):119-122

Dimethyl fumarate in treating relapsing-remitting multiple sclerosis

Eva Meluzínová¹, Martin Bortlík²

¹ Neurologická klinika 2. LF UK a FN Motol, Praha

² Klinické a výzkumné centrum pro střevní záněty ISCARE a 1. LF UK, Praha

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS). With early initiation

of treatment, it is possible to slow down the whole immunopathological process. Treatment is initiated with first-line drugs optimally after

the first symptom of disease. Patients in whom the effect of this therapy is inadequate require escalation to second-line drugs. In February

2014, dimethyl fumarate (DMF) was registered for the treatment of relapsing-remitting MS (RR-MS) in the Czech Republic. It is an oral medication

that meets the criterion of efficacy while having good tolerance, safety, and the capacity to affect both the inflammation and the

process of neurodegeneration. In the Czech Republic, this agent is among the second-line drugs. If the patient does not tolerate injection

drugs used in the first line, it is possible to replace them with dimethyl fumarate.

therapy, oral treatment, randomized clinical trial.

Keywords: multiple sclerosis, chronic inflammation, neurodegeneration, neuroprotection, dimethyl fumarate, disease-modifying

Published: December 1, 2015  Show citation